Ulcerative colitis (UC) is a long-term disorder that associated with overactivation of immunoinflammatory system, ending with ulcer in the large intestine. This study aimed to compare the activity and toxicity of different TNF-alpha inhibitors in a sample of Iraqi patients having active ulcerative colitis. Fifty patients with refractory ulcerative colitis were randomly distributed to either group I (n=25): on adalimumab injection (160/80mg) or group II (n=25): on infliximab injection (5mg/kg) along the term of induction. Clinical remission was considered as the primary subjective parameter, while clinical response; mucosal healing; and subscores of mild status were regarded as secondary subjective parameters. Fractional Mayo score; Inflammatory Bowel Disease Questionnaire (IBDQ); and safety profile were also evaluated. A 24% versus 28% patients were in clinical remission for those receiving adalimumab and infliximab, respectively (P>0.05), while 48% versus 52% patients were in clinical response for those receiving adalimumab and infliximab, respectively (P>0.05), and 40% of patients acquired mucosal healing for both adalimumab and infliximab arms (P>0.05).Scores of physician assessment and rectal bleeding was shown to be markedly higher in infliximab patients (P
Key words: ulcerative colitis, clinical remission, safety profile, adalimumab, infliximab.
|
